Relapse after glofitamab, a novel unmet medical need with high rates of CD20 loss.

Autor: Carlo-Stella C; Department of Biomedical Sciences, Humanitas University, Milan, Italy.; Department of Oncology and Hematology, IRCCS Humanitas Research Hospital, Milan, Italy.
Jazyk: angličtina
Zdroj: British journal of haematology [Br J Haematol] 2024 Jul; Vol. 205 (1), pp. 17-19. Date of Electronic Publication: 2024 May 30.
DOI: 10.1111/bjh.19503
Abstrakt: The prognosis of r/r DLBCL has changed substantially over the past decade due to the introduction of T-cell-activating therapies. Besides generating a new curative perspective for a proportion of r/r DLBCL, chimeric antigen receptor T-cell therapy and bispecific antibodies are generating new unmet needs. The report by Grigg and colleagues now shows that glofitamab-refractory, CD20-negative patients represent a new unmet medical need requiring therapeutic targets other than CD20 and novel therapies to reduce the risk of CD20 loss. Commentary on: Grigg et al. Relapse after glofitamab has a poor prognosis, and rates of CD20 loss are high. Br J Haematol 2024;205:122-126.
(© 2024 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: